Full text is available at the source.
Glucagon-Like Peptide 1 Receptor Agonists Are Not Associated With an Increased Risk of Ileus or Intestinal Obstruction in Patients with Inflammatory Bowel Disease—A Danish Nationwide Cohort Study
Glucagon-Like Peptide 1 Drugs Are Not Linked to Higher Risk of Intestinal Blockage in People with Inflammatory Bowel Disease
AI simplified
Abstract
GLP-1 receptor agonist exposure was not associated with an increased risk of ileus or intestinal obstruction in patients with inflammatory bowel disease.
- The prevalence of obesity is increasing globally, including among individuals with inflammatory bowel disease (IBD).
- GLP-1 receptor agonists (GLP-1RAs) are being considered as anti-obesity medications due to their potential weight-lowering effects.
- Concerns exist about the risk of severe side effects, such as ileus and intestinal obstruction, when using GLP-1RAs.
- A nationwide study in Denmark analyzed patients with IBD who were exposed to GLP-1RAs using health registries.
- The analysis adjusted for various factors including age, sex, type of IBD, and previous medical history.
AI simplified